Developing New Outcome Measures, Functional Biomarkers & Clinical Research Regulatory Frameworks for Disease-Modifying Therapeutics Across Neurodevelopmental & Rare, Genetic CNS Disorders

With more clinical data emerging, neurodevelopmental drug development is advancing from hypotheticals to real-life clinical results, outcomes, and functional biomarkers, catapulting this critical field forwards.

Join 100+ peers this November at the 2nd Rare CNS & Neurodevelopmental Drug Development Summit – the only industry dedicated drug development forum for large pharma, biotech, academia, and patient advocacy groups, paving the way towards symptomatic and successful disease modifying treatments.

Tightly focused on industry progress, stakeholders will explore ASOs, gene therapies and small molecules across autistic syndromes and seizure phenotypes at this unique drug sponsor conference.

Don’t miss out on this definitive opportunity to collaborate with patient groups and gain regulatory clarity on clinical trial design, endpoints and delivery and toxicity concerns as well as deep diving into functional and molecular biomarkers, emerging therapeutic targets and translational biology.

If you are working towards treatments for rare CNS and neurodevelopmental disorders, including (but not limited to) Angelman Syndrome, Rett syndrome, Fragile X, Dravet Syndrome and CDKL5 Syndrome or discovering new frontiers in anti-epileptic therapeutics, this is the platform you need.

To know more visit: https://ter.li/9yzux5